Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BL173-hUMSCs
- Development stage
- Unknown
- Lead developer
- Renji Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
BL173-hUMSCs is an allogeneic cell therapy product composed of human umbilical cord-derived mesenchymal stem cells (hUMSCs). Developed by Renji Hospital of Shanghai Jiaotong University School of Medicine, it is being evaluated for the treatment of knee osteoarthritis. The therapy involves the intra-articular administration of these multipotent cells, which are intended to alleviate pain and improve joint function by modulating the inflammatory environment within the joint and potentially promoting the regeneration of damaged cartilage. The product is currently in Phase 2 clinical development.
- Other names
- human umbilical cord mesenchymal stem cellshUMSCs
Beyond the preview
Go deeper on BL173-hUMSCs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BL173-hUMSCs.